Sore Throat News and Research

RSS

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.

19 Oct 2013

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.

11 Oct 2013

Research roundup: Health law's effects on consumer spending; Mass. experience finds increased use of laparoscopic surgery

The authors find that average out-of-pocket spending is expected to decrease for all groups considered in the analysis, although decreases in out-of-pocket spending will be largest for those who would otherwise be uninsured.

5 Oct 2013

Doctors prescribe antibiotics for sore throats and acute bronchitis, say researchers

A vast majority of people who see their doctors for sore throats or acute bronchitis receive antibiotics, yet only a small percentage should, according to analyses of two major national surveys being presented at IDWeek 2013-. Those illnesses usually are caused by viruses, and antibiotics - which only treat bacterial infections - do not help.

5 Oct 2013

Diabetes puts you at increased risk of flu-related complications

There are certain groups of people who are at risk of serious flu complications each year, including those with diabetes.

30 Sep 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes.

24 Sep 2013

TGA of Australia approves Vertex Pharmaceuticals' KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.

10 Jul 2013

Viewpoints: Health care's hidden consensus; Examining the fee-for-service payment system; Alternative medicine's allure

The politicians' consensus is that health care reform shouldn't alter or disrupt the way the majority of Americans get their insurance today. ... The policy consensus, though, is that the status quo is actually the problem, and that it deserves to be threatened, undermined and replaced as expeditiously as possible. Wonks of the left and right disagree on what that replacement should look like. But they're united in regarding employer-provided coverage as an unsustainable relic (Ross Douthat, 7/6).

9 Jul 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

CREON Delayed-Release Capsules now available in US for patients with EPI

AbbVie announced that a new, higher-dose capsule of CREON (pancrelipase) Delayed-Release Capsules is commercially available in the United States. The U.S. Food and Drug Administration recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.

31 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

Changing toothbrush will not prevent sore throat

Word on the street has it you should replace your toothbrush after suffering from a cold, the flu or a bout of strep throat. That may not be necessary - at least when it comes to sore throats, according to a study to be presented Saturday, May 4, at the Pediatric Academic Societies (PAS) annual meeting in Washington, DC.

6 May 2013

Influenza drug: an interview with Dr Jenny McKimm-Breschkin, CSIRO

Influenza or flu for short is caused by a family of viruses, which can be called influenza A or influenza B. Influenza A viruses are found in humans, animals – like swine and horses- and mostly aquatic birds. Influenza B is only found in humans.

11 Mar 2013

Weill Cornell receives NIMH grant to discover novel biomarkers for chronic fatigue syndrome

Weill Cornell Medical College has been awarded more than $1.9 million by the National Institute of Mental Health of the National Institutes of Health to lead an innovative research study using advanced neuroimaging and clinical evaluations of patients with chronic fatigue syndrome (CFS).

8 Mar 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Wichita State associate professor writes two books about flu

The flu: It's a popular topic of conversation lately, as most people probably know someone who has gotten sick this winter. But for Wichita State associate professor George Dehner, the flu is a year-round focus. Dehner, who teaches world and environmental history, recently wrote two books about the flu.

11 Feb 2013

NSU-COM to hold grand opening for America's first Institute for Neuro Immune Medicine

Nova Southeastern University's College of Osteopathic Medicine (NSU-COM) will hold a grand opening for America's first Institute for Neuro Immune Medicine on Feb. 12.

5 Feb 2013

Ten common notions concerning colds and flu

The cold and flu season has hit early and hard this year. As the number of people infected continues to increase, so does the number of internet searches for ways to prevent or limit the duration of viral illnesses. But, what is fact and what is fiction?

1 Feb 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013